Drug Study Ambroxol
Drug Study Ambroxol
Drug Study Ambroxol
Apego January 27, 2014 N-40 Patients name: Casugudan Name of Drug Generic Name: Ambroxol Hydrochlori de Trade Name: Mucosolvan and Mucoangin Availability: Tablets30 mg; Classification of Mechanism of Action Drug Therapeutic: It enhances Mucolytic pulmonary surfactant Pregnancy production Category A and stimulates ciliary activity. These actions result in improved mucus flow and transport (mucociliary clearance). Enhancement of fluid secretion and mucociliary clearance facilitates expectoration and eases cough. Indication Adjuvant therapy in patients with abnormal, viscid, or inspissated mucous secretions in acute and chronic bronchopulmonary diseases, and in pulmonary complications of cystic fibrosis and surgery, tracheostomy, and atelectasis. Contraindications Side Effects Nursing Responsibilities Monitor for S&S of aspiration of excess secretions, and for bronchospasm (unpredictable);withhold drug and notify physician immediately if either occur. Lab tests: Monitor ABGs, pulmonary functions and pulse oximetry as indicated. Have suction apparatus immediately available. Increased volume of respiratory tract fluid may be liberated; suction or endotracheal aspiration may be necessary to establish and maintain an open airway. Patient & Family Education Report difficulty with clearing the airway or any other respiratory distress
Should not be There are no such used in harmful side effects patients known of the medicine. It is to be usually well hypersensitiv e tolerated. In some to ambroxol or cases, nausea and other vomiting might components of occur. the formulation. There are no absolute contraindicatio n but in patients with gastric ulceration relative caution should be observed.